AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PYC THERAPEUTICS LTD

1.495

+0.0050.34%

Volume:915.46K

Turnover:1.37M

Market Cap:1.40B

PE:-17.57

High:1.505

Open:1.500

Low:1.490

Close:1.490

52wk High:1.755

52wk Low:0.847

Shares:938.04M

Float Shares:348.08M

Volume Ratio:1.00

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.085

EPS(LYR):-0.101

ROE:-47.55%

ROA:-28.68%

PB:9.53

PE(LYR):-14.87

Loading ...

Overview Company News Filings

PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative

Simply Wall St.

BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million

PYC Therapeutics Ltd - Hy Revenues From Ordinary Activities a$11.0 Mln

THOMSON REUTERS

PYC Therapeutics Ltd-Retail Offer Booklet

THOMSON REUTERS

PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer

MT Newswires Live

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

PYC Therapeutics Announces Raising Up To A$653 Million

BRIEF-PYC Therapeutics Seeks Trading Halt

PYC Therapeutics Ltd - Raising up to a$653M at a$1.50 per Share

THOMSON REUTERS

PYC Therapeutics Ltd - Seeks Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership You Need To Know

Simply Wall St.

PYC Therapeutics Advances Work on Three Drug Candidates in December 2025 Quarter

MT Newswires Live

PYC Therapeutics Ltd-Offer to Issue Director Options & Appendix 3Y

THOMSON REUTERS

PYC Therapeutics Ltd-Update - Notification Regarding Unquoted Securities - Pyc

THOMSON REUTERS

PYC Therapeutics Ltd-Offer to Issue Director Options and Appendix 3Y

THOMSON REUTERS

Exploring High Growth Tech Stocks in Australia Featuring Three Prominent Companies

Simply Wall St.

ASX Growth Stocks With High Insider Confidence For December 2025

Simply Wall St.

Breakeven On The Horizon For PYC Therapeutics Limited (ASX:PYC)

Simply Wall St.

PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study

MT Newswires Live

Insider Buys Additional AU$200k In PYC Therapeutics Stock

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PYC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":1.495,"timestamp":1771996320000,"preClose":1.49,"halted":0,"volume":915460,"delay":0,"changeRate":0.0033557046979866547,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":938042648,"eps":-0.085066,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"02-25 16:12:00 AEDT","open":1.5,"high":1.505,"low":1.49,"amount":1370675,"amplitude":0.010067,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.085066,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.49,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":1.000303546026109,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-28.68%","roe":"-47.55%","lyrEps":-0.100508,"volumeRatio":1.000303546026109,"shares":938042648,"dividePrice":0,"high":1.505,"amplitude":0.010067,"preClose":1.49,"low":1.49,"week52Low":0.847,"pbRate":"9.53","psRate":"68.21","week52High":1.755,"institutionHeld":0,"latestPrice":1.495,"eps":-0.085066,"divideRate":0,"volume":915460,"delay":0,"ttmEps":-0.085066,"open":1.5,"prevYearClose":1.655,"prevWeekClose":1.5,"prevMonthClose":1.6,"prevQuarterClose":1.655,"fiveDayClose":1.5,"twentyDayClose":1.66,"sixtyDayClose":1.535,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613715809","title":"PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715809?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:29","pubTimestamp":1771925358,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing heavily to progress its pipeline. Over recent reporting periods, revenue has moved from A$13.2 million in H2 2024 to A$11.8 million in H1 2025 and A$11.7 million in H2 2025, while basic EPS losses have shifted from A$0.055 in H2 2024 to A$0.0548 in H1 2025 and A$0.046 in H2 2025. This gives investors a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-h1-2026-losses-highlight-ongoing-investment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BLSG","BLSX","BK4112","BK4007","BK4139","PYC.AU","BK4539"],"gpt_icon":0},{"id":"2613278375","title":"BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613278375","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613278375?lang=en_us&edition=fundamental","pubTime":"2026-02-23 18:10","pubTimestamp":1771841448,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 MillionFeb 23 (Reuters) - PYC Therapeutics Ltd PYC.AX:HY REVENUES FROM ORDINARY ACTIVITIES A$11.0 MILLIONHY LOSS ATTRIBUTABLE A$22.8 MILLIONFurther company coverage: PYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2613882207","title":"PYC Therapeutics Ltd -  Hy Revenues From Ordinary Activities a$11.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2613882207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613882207?lang=en_us&edition=fundamental","pubTime":"2026-02-23 15:48","pubTimestamp":1771832921,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2610350383","title":"PYC Therapeutics Ltd-Retail Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2610350383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610350383?lang=en_us&edition=fundamental","pubTime":"2026-02-09 06:21","pubTimestamp":1770589319,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUE3NBC6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2608738211","title":"PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608738211","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608738211?lang=en_us&edition=fundamental","pubTime":"2026-02-04 08:55","pubTimestamp":1770166525,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.The funds will be used to extend the company's cash runw","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","PYC.AU","BK4139","BK7067","BK4539","BK4007"],"gpt_icon":0},{"id":"2608307388","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608307388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608307388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:06","pubTimestamp":1770145565,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dynamic environment, high-growth tech stocks can offer intriguing opportunities for investors seeking innovation and resilience amidst economic shifts and evolving global strategies.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","CGS.AU","XJO.AU","PYC.AU","BK7094","XKO.AU","CUV.AU","XAO.AU","BK7508"],"gpt_icon":0},{"id":"2608548728","title":"PYC Therapeutics Announces Raising Up To A$653 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608548728","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608548728?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:00","pubTimestamp":1770022835,"startTime":"0","endTime":"0","summary":"Feb 2 (Reuters) - PYC Therapeutics Ltd ::*RAISING UP TO A$653M AT A$1.50 PER SHARE*Further company coverage: PYC.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 02-FEB-202608:45:31 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nRSD9C83Pw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2608385188","title":"BRIEF-PYC Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608385188?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:41","pubTimestamp":1770021702,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Seeks Trading HaltFeb 2 (Reuters) - PYC Therapeutics Ltd PYC.AX:SEEKS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: PYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YX036:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2608882856","title":"PYC Therapeutics Ltd -  Raising up to a$653M at a$1.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882856","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882856?lang=en_us&edition=fundamental","pubTime":"2026-02-02 06:41","pubTimestamp":1769985674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YV1T1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2608842308","title":"PYC Therapeutics Ltd - Seeks Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608842308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608842308?lang=en_us&edition=fundamental","pubTime":"2026-02-02 06:17","pubTimestamp":1769984235,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YX036:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2606722043","title":"ASX Growth Companies With High Insider Ownership You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2606722043","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606722043?lang=en_us&edition=fundamental","pubTime":"2026-01-27 03:08","pubTimestamp":1769454533,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a week marked by global economic uncertainties and fluctuating commodity prices, investors are keenly observing how local indices respond to international influences like U.S. market gains and rising gold prices. In this context, growth companies with high insider ownership on the ASX present intriguing opportunities, as they often reflect strong internal confidence and alignment with shareholder interests amidst such volatile conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/asx-growth-companies-with-high-insider-ownership-you-need-to-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/asx-growth-companies-with-high-insider-ownership-you-need-to-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BB1.AU","WZR.AU","BK7117","EIQ.AU","BK7067","BK7122","AEM.AU","3DP.AU","TTT.AU","PYC.AU","BK7154","BK7093","UNI.AU","P1E.AU","BK7036","AV1.AU","CMW.AU","NWF.AU","CFA.SI","BK7116","SEA.AU","BK7142","BK7016","BK7017","BK7094","BK7021"],"gpt_icon":0},{"id":"2605447462","title":"PYC Therapeutics Advances Work on Three Drug Candidates in December 2025 Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2605447462","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605447462?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:41","pubTimestamp":1769136086,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) advanced work on its three investigational drug candidates in clinical development during the quarter ended Dec. 31, 2025, with a fourth expected to enter human trials in th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","BK4539","BK7067","PYC.AU"],"gpt_icon":0},{"id":"2603037085","title":"PYC Therapeutics Ltd-Offer to Issue Director Options & Appendix 3Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2603037085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603037085?lang=en_us&edition=fundamental","pubTime":"2026-01-13 15:28","pubTimestamp":1768289318,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUEB7ZWKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2603777525","title":"PYC Therapeutics Ltd-Update - Notification Regarding Unquoted Securities - Pyc","url":"https://stock-news.laohu8.com/highlight/detail?id=2603777525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603777525?lang=en_us&edition=fundamental","pubTime":"2026-01-13 14:01","pubTimestamp":1768284104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUEBY7GHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2602234577","title":"PYC Therapeutics Ltd-Offer to Issue Director Options and Appendix 3Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2602234577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602234577?lang=en_us&edition=fundamental","pubTime":"2026-01-09 11:51","pubTimestamp":1767930679,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUEWPLZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2595774558","title":"Exploring High Growth Tech Stocks in Australia Featuring Three Prominent Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2595774558","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595774558?lang=en_us&edition=fundamental","pubTime":"2025-12-31 03:06","pubTimestamp":1767121572,"startTime":"0","endTime":"0","summary":"As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high growth tech stocks in Australia can offer intriguing opportunities for investors seeking innovation and potential expansion, particularly when these companies demonstrate resilience and adaptability amidst fluctuating economic conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-high-growth-tech-stocks-in-australia-featuring-thr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-high-growth-tech-stocks-in-australia-featuring-thr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","FCL.AU","PYC.AU","XKO.AU","XAO.AU","RUL.AU","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2595927496","title":"ASX Growth Stocks With High Insider Confidence For December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2595927496","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595927496?lang=en_us&edition=fundamental","pubTime":"2025-12-29 03:08","pubTimestamp":1766948890,"startTime":"0","endTime":"0","summary":"As the Australian market winds down for the holiday season, with a slight dip attributed to profit-taking and global indices nearing record highs, investors are reflecting on their portfolios and considering new opportunities for growth. In such an environment, stocks with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the company best.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-confidence-for-december-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-confidence-for-december-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7095","BK7094","LM8.AU","PNV.AU","BK7126","AV1.AU","BK7093","UNI.AU","BK7036","BK7104","TTT.AU","BK7116","BK7016","BB1.AU","BK7506","SEA.AU","3DP.AU","BK7021","NWF.AU","BK7117","WZR.AU","BK7067","EIQ.AU","EMR.AU","PYC.AU"],"gpt_icon":0},{"id":"2594407514","title":"Breakeven On The Horizon For PYC Therapeutics Limited (ASX:PYC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2594407514","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594407514?lang=en_us&edition=fundamental","pubTime":"2025-12-25 04:14","pubTimestamp":1766607256,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse PYC Therapeutics Limited's ( ASX:PYC ) business as it appears the company...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/breakeven-on-the-horizon-for-pyc-therapeutics-limited-asxpyc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/breakeven-on-the-horizon-for-pyc-therapeutics-limited-asxpyc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2592113135","title":"PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592113135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592113135?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:17","pubTimestamp":1766107027,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4007","BK4539","PYC.AU","BK7067"],"gpt_icon":0},{"id":"2587148759","title":"Insider Buys Additional AU$200k In PYC Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2587148759","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587148759?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:35","pubTimestamp":1764362124,"startTime":"0","endTime":"0","summary":"Investors who take an interest in PYC Therapeutics Limited ( ASX:PYC ) should definitely note that the CEO & Executive...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/insider-buys-additional-au200k-in-pyc-therapeutics-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/insider-buys-additional-au200k-in-pyc-therapeutics-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU","BK4007","BK4139","BK7067","BK4539","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}